Počet záznamů: 1
The role of m6A and m6Am RNA modifications in the pathogenesis of diabetes mellitus
- 1.
SYSNO ASEP 0573796 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název The role of m6A and m6Am RNA modifications in the pathogenesis of diabetes mellitus Tvůrce(i) Benák, Daniel (FGU-C) ORCID, RID
Benáková, Štěpánka (FGU-C) ORCID, RID
Plecitá-Hlavatá, Lydie (FGU-C) RID, ORCID
Hlaváčková, Markéta (FGU-C) RID, ORCIDČíslo článku 1223583 Zdroj.dok. Frontiers in Endocrinology. - : Frontiers Media - ISSN 1664-2392
Roč. 14, July (2023)Poč.str. 11 s. Jazyk dok. eng - angličtina Země vyd. CH - Švýcarsko Klíč. slova type 2 diabetes mellitus ; T2DM ; diabetes ; RNA ; epigenetics ; epitranscriptomics ; m6A ; m6Am Obor OECD Physiology (including cytology) CEP GJ19-04790Y GA ČR - Grantová agentura ČR LX22NPO5104 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy GA22-11439S GA ČR - Grantová agentura ČR Způsob publikování Open access Institucionální podpora FGU-C - RVO:67985823 UT WOS 001030189600001 EID SCOPUS 85165287408 DOI https://doi.org/10.3389/fendo.2023.1223583 Anotace The rapidly developing research field of epitranscriptomics has recently emerged into the spotlight of researchers due to its vast regulatory effects on gene expression and thereby cellular physiology and pathophysiology. N6-methyladenosine (m6A) and N6,2’-O-dimethyladenosine (m6Am) are among the most prevalent and well-characterized modified nucleosides in eukaryotic RNA. Both of these modifications are dynamically regulated by a complex set of epitranscriptomic regulators called writers, readers, and erasers. Altered levels of m6A and also several regulatory proteins were already associated with diabetic tissues. This review summarizes the current knowledge and gaps about m6A and m6Am modifications and their respective regulators in the pathophysiology of diabetes mellitus. It focuses mainly on the more prevalent type 2 diabetes mellitus (T2DM) and its treatment by metformin, the first-line antidiabetic agent. A better understanding of epitranscriptomic modifications in this highly prevalent disease deserves further investigation and might reveal clinically relevant discoveries in the future. Pracoviště Fyziologický ústav Kontakt Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Rok sběru 2024 Elektronická adresa https://doi.org/10.3389/fendo.2023.1223583
Počet záznamů: 1